Research output per year
Research output per year
Personal profile
Headline
CLINICAL INSTRUCTOR | Dermatology
Fingerprint
Dive into the research topics where Michael Cameron is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
Ständer, S., Kwatra, S. G., Silverberg, J. I., Simpson, E. L., Thyssen, J. P., Yosipovitch, G., Zhang, F., Cameron, M. C., Cella, R. R., Valdez, H., DiBonaventura, M. & Feeney, C., Jan 2023, In: American Journal of Clinical Dermatology. 24, 1, p. 97-107 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Blauvelt, A., Silverberg, J. I., Lynde, C. W., Bieber, T., Eisman, S., Zdybski, J., Gubelin, W., Simpson, E. L., Valenzuela, F., Criado, P. R., Lebwohl, M. G., Feeney, C., Khan, T., Biswas, P., DiBonaventura, M., Valdez, H., Cameron, M. C. & Rojo, R., Jan 2022, In: Journal of the American Academy of Dermatology. 86, 1, p. 104-112 9 p.Research output: Contribution to journal › Article › peer-review
Open Access45 Scopus citations -
Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
Blauvelt, A., Boguniewicz, M., Brunner, P. M., Luna, P. C., Biswas, P., DiBonaventura, M., Farooqui, S. A., Rojo, R. & Cameron, M. C., 2022, In: Journal of Dermatological Treatment. 33, 5, p. 2605-2613 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
Reich, K., Lio, P. A., Bissonnette, R., Alexis, A. F., Lebwohl, M. G., Pink, A. E., Kabashima, K., Boguniewicz, M., Nowicki, R. J., Valdez, H., Zhang, F., DiBonaventura, M., Cameron, M. C. & Clibborn, C., Dec 2022, In: Journal of Allergy and Clinical Immunology: In Practice. 10, 12, p. 3228-3237.e2Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
Shi, V. Y., Bhutani, T., Fonacier, L., Deleuran, M., Shumack, S., Valdez, H., Zhang, F., Chan, G. L., Cameron, M. C. & Yin, N. C., Aug 2022, In: Journal of the American Academy of Dermatology. 87, 2, p. 351-358 8 p.Research output: Contribution to journal › Article › peer-review
Open Access27 Scopus citations
Press/Media
-
-
Dermatology Providers Share Their Best Pearls From Fall Clinical for PAs and NPs
Joshua Zeichner, Mark Lebwohl & Michael Cameron
1/06/23
1 item of Media coverage
Press/Media
-
9 expert-recommend sunburn treatments to relieve pain and calm itching
17/05/23
1 item of Media coverage
Press/Media
-
Atopic Dermatitis Overview; Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.
28/04/23
1 item of Media coverage
Press/Media
-